6 Dimensions Capital led a round for the miniprotein drug developer, founded by Harvard researcher Gregory Verdine.

FogPharma, a US-based miniprotein developer based on research at Harvard University, closed a $66m series B round on Wednesday led by 6 Dimensions Capital.

6 Dimensions Capital, the fund formed by pharmaceutical firm WuXi AppTec and VC firm Frontline BioVentures, was joined by property developer Nan Fung Group, conglomerate Alphabet’s GV unit and WuXi AppTec’s WuXi AppTec Corporate Ventures subsidiary.

Blue Pool Capital, Horizons Ventures, Leerink Partners, Deerfield Management, Boyu Capital and unnamed non-institutional investors also contributed funding.

Founded in…